Signalling to eIF4E in cancer

Biochemical Society Transactions

Volumn 43, Issue , 2015, Pages 763-772

  Siddiqui, Nadeem ^a   Sonenberg, Nahum ^a  

^a MCGILL UNIVERSITY   (Canada)

Author keywords

Cancer therapy; Eukaryotic translation initiation factor 4E (eIF4E); Eukaryotic translation initiation factor 4E binding proteins (4E BPs); Mechanistic mammalian target of rapamycin (mTOR); Mitogen activated protein kinaseinteracting kinase 1 2 (Mnk1 2); Phospho 4E

Indexed keywords

ANTINEOPLASTIC AGENT; INITIATION FACTOR 4E; MAMMALIAN TARGET OF RAPAMYCIN; CAPPED RNA; MESSENGER RNA; TUMOR PROTEIN;

ARTICLE; CLINICAL TRIAL (TOPIC); ENZYME PHOSPHORYLATION; ENZYME REGULATION; HUMAN; MOLECULARLY TARGETED THERAPY; NEOPLASM; NONHUMAN; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; ANIMAL; ANTAGONISTS AND INHIBITORS; AWARDS AND PRIZES; BIOCHEMISTRY; BIOLOGICAL MODEL; CARCINOGENESIS; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; HEALTH CARE ORGANIZATION; HISTORY; METABOLISM; NEOPLASMS; RNA TRANSLATION; UNITED KINGDOM;

ANIMALS; ANNIVERSARIES AND SPECIAL EVENTS; ANTINEOPLASTIC AGENTS; AWARDS AND PRIZES; BIOCHEMISTRY; CARCINOGENESIS; EUKARYOTIC INITIATION FACTOR-4E; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MODELS, BIOLOGICAL; NEOPLASM PROTEINS; NEOPLASMS; PEPTIDE CHAIN INITIATION, TRANSLATIONAL; RNA CAPS; RNA, MESSENGER; SIGNAL TRANSDUCTION; SOCIETIES, SCIENTIFIC; UNITED KINGDOM;

EID: 84947292931     PISSN: 03005127     EISSN: 14708752     Source Type: Journal    
DOI: 10.1042/BST20150126     Document Type: Article

References (116)

1. Mathews, M.B., Sonenberg, N. and Hershey, J. (2007) Translation Control in Biology and Medicine. Cold Spring Harbor Monograph Series 48, Cold Spring Harbor, NY
2. Hinnebusch, A.G., Asano, K., Olsen, D.S., Phan, L., Nielsen, K.H. and Valasek, L. (2004) Study of translational control of eukaryotic gene expression using yeast. Ann. N.Y. Acad. Sci. 1038, 60-74 CrossRef PubMed
3. Dever, T.E. and Green, R. (2012) The elongation, termination, and recycling phases of translation in eukaryotes. Cold Spring Harb. Perspect. Biol. 4, a013706 CrossRef PubMed
4. Jackson, R.J., Hellen, C.U. and Pestova, T.V. (2010) The mechanism of eukaryotic translation initiation and principles of its regulation. N. Rev. Mol. Cell Biol. 11, 113-127 CrossRef
5. Sonenberg, N. and Hinnebusch, A.G. (2009) Regulation of translation initiation in eukaryotes: Mechanisms and biological targets. Cell 136, 731-745 CrossRef PubMed
6. Topisirovic, I., Svitkin, Y.V., Sonenberg, N. and Shatkin, A.J. (2011) Cap and cap-binding proteins in the control of gene expression. Wiley Interdiscip. Rev. RNA 2, 277-298 CrossRef PubMed
7. Gingras, A.C., Raught, B. and Sonenberg, N. (1999) eIF4 initiation factors: Effectors of mRNA recruitment to ribosomes and regulators of translation. Annu. Rev. Biochem. 68, 913-963 CrossRef PubMed
8. Parsyan, A., Svitkin, Y., Shahbazian, D., Gkogkas, C., Lasko, P., Merrick, W.C. and Sonenberg, N. (2011) mRNA helicases: The tacticians of translational control. Nat. Rev. Mol. Cell Biol. 12, 235-245 CrossRef PubMed
9. Hinnebusch, A.G. (2014) The scanning mechanism of eukaryotic translation initiation. Annu. Rev. Biochem. 83, 779-812 CrossRef PubMed
10. Tarun, Jr, S.Z. and Sachs, A.B. (1996) Association of the yeast poly(A) tail binding protein with translation initiation factor eIF-4G. EMBO J. 15, 7168-7177 PubMed
11. Kahvejian, A., Svitkin, Y.V., Sukarieh, R., M'Boutchou, M.N. and Sonenberg, N. (2005) Mammalian poly(A)-binding protein is a eukaryotic translation initiation factor, which acts via multiple mechanisms. Genes Dev. 19, 104-113 CrossRef PubMed
12. Bhat, M., Robichaud, N., Hulea, L., Sonenberg, N., Pelletier, J. and Topisirovic, I. (2015) Targeting the translation machinery in cancer. Nat. Rev. Drug Discov. 14, 261-278 CrossRef PubMed
13. Graff, J.R., Konicek, B.W., Carter, J.H. and Marcusson, E.G. (2008) Targeting the eukaryotic translation initiation factor 4E for cancer therapy. Cancer Res. 68, 631-634 CrossRef PubMed
14. Gehrke, L., Auron, P.E., Quigley, G.J., Rich, A. and Sonenberg, N. (1983) 5'-Conformation of capped alfalfa mosaic virus ribonucleic acid 4 may reflect its independence of the cap structure or of cap-binding protein for efficient translation. Biochemistry 22, 5157-5164 CrossRef PubMed
15. Payvar, F. and Schimke, R.T. (1979) Methylmercury hydroxide enhancement of translation and transcription of ovalbumin and conalbumin mRNA's. J. Biol. Chem. 254, 7636-7642 PubMed
16. Pelletier, J. and Sonenberg, N. (1985) Insertion mutagenesis to increase secondary structure within the 5' noncoding region of a eukaryotic mRNA reduces translational efficiency. Cell 40, 515-526 CrossRef PubMed
17. Goossen, B., Caughman, S.W., Harford, J.B., Klausner, R.D. and Hentze, M.W. (1990) Translational repression by a complex between the iron-responsive element of ferritin mRNA and its specific cytoplasmic binding protein is position-dependent in vivo. EMBO J. 9, 4127-4133 PubMed
18. Sagliocco, F.A., Vega Laso, M.R., Zhu, D., Tuite, M.F., McCarthy, J.E. and Brown, A.J. (1993) The influence of 5'-secondary structures upon ribosome binding to mRNA during translation in yeast. J. Biol. Chem. 268, 26522-26530 PubMed
19. Babendure, J.R., Babendure, J.L., Ding, J.H. and Tsien, R.Y. (2006) Control of mammalian translation by mRNA structure near caps. RNA 12, 851-861 CrossRef PubMed
20. Kozak, M. (1986) Influences of mRNA secondary structure on initiation by eukaryotic ribosomes. Proc. Natl. Acad. Sci. U.S.A. 83, 2850-2854 CrossRef PubMed
21. Koromilas, A.E., Lazaris-Karatzas, A. and Sonenberg, N. (1992) mRNAs containing extensive secondary structure in their 5' non-coding region translate efficiently in cells overexpressing initiation factor eIF-4E. EMBO J. 11, 4153-4158 PubMed
22. Svitkin, Y.V., Pause, A., Haghighat, A., Pyronnet, S., Witherell, G., Belsham, G.J. and Sonenberg, N. (2001) The requirement for eukaryotic initiation factor 4A (elF4A) in translation is in direct proportion to the degree of mRNA 5' secondary structure. RNA 7, 382-394 CrossRef PubMed
23. Feoktistova, K., Tuvshintogs, E., Do, A. and Fraser, C.S. (2013) Human eIF4E promotes mRNA restructuring by stimulating eIF4A helicase activity. Proc. Natl. Acad. Sci. U.S.A. 110, 13339-13344 CrossRef PubMed
24. Thoreen, C.C., Chantranupong, L., Keys, H.R., Wang, T., Gray, N.S. and Sabatini, D.M. (2012) A unifying model for mTORC1-mediated regulation of mRNA translation. Nature 485, 109-113 CrossRef PubMed
25. Hsieh, A.C., Liu, Y., Edlind, M.P., Ingolia, N.T., Janes, M.R., Sher, A., Shi, E.Y., Stumpf, C.R., Christensen, C., Bonham, M.J. et al. (2012) The translational landscape of mTOR signalling steers cancer initiation and metastasis. Nature 485, 55-61 CrossRef PubMed
26. Miloslavski, R., Cohen, E., Avraham, A., Iluz, Y., Hayouka, Z., Kasir, J., Mudhasani, R., Jones, S.N., Cybulski, N., Ruegg, M.A. et al. (2014) Oxygen sufficiency controls TOP mRNA translation via the TSC-Rheb-mTOR pathway in a 4E-BP-independent manner. J. Mol. Cell Biol. 6, 255-266 CrossRef PubMed
27. Meyuhas, O. and Kahan, T. (2014) The race to decipher the top secrets of TOP mRNAs. Biochim. Biophys. Acta. 1849, 801-811 CrossRef PubMed
28. Mader, S., Lee, H., Pause, A. and Sonenberg, N. (1995) The translation initiation factor eIF-4E binds to a common motif shared by the translation factor eIF-4 gamma and the translational repressors 4E-binding proteins. Mol. Cell. Biol. 15, 4990-4997 PubMed
29. Pause, A., Belsham, G.J., Gingras, A.C., Donze, O., Lin, T.A., Lawrence, Jr, J.C. and Sonenberg, N. (1994) Insulin-dependent stimulation of protein synthesis by phosphorylation of a regulator of 5'-cap function. Nature 371, 762-767 CrossRef PubMed
30. Poulin, F., Gingras, A.C., Olsen, H., Chevalier, S. and Sonenberg, N. (1998) 4E-BP3, a new member of the eukaryotic initiation factor 4E-binding protein family. J. Biol. Chem. 273, 14002-14007 CrossRef PubMed
31. Hay, N. and Sonenberg, N. (2004) Upstream and downstream of mTOR. Genes Dev. 18, 1926-1945 CrossRef PubMed
32. Laplante, M. and Sabatini, D.M. (2012) mTOR signaling in growth control and disease. Cell 149, 274-293 CrossRef PubMed
33. Caron, E., Ghosh, S., Matsuoka, Y., Ashton-Beaucage, D., Therrien, M., Lemieux, S., Perreault, C., Roux, P.P. and Kitano, H. (2010) A comprehensive map of the mTOR signaling network. Mol. Syst. Biol. 6, 453 CrossRef PubMed
34. Wullschleger, S., Loewith, R. and Hall, M.N. (2006) TOR signaling in growth and metabolism. Cell 124, 471-484 CrossRef PubMed
35. Kim, D.H., Sarbassov, D.D., Ali, S.M., Latek, R.R., Guntur, K.V., Erdjument-Bromage, H., Tempst, P. and Sabatini, D.M. (2003) GbetaL, a positive regulator of the rapamycin-sensitive pathway required for the nutrient-sensitive interaction between raptor and mTOR. Mol. Cell 11, 895-904 CrossRef PubMed
36. Ma, X.M. and Blenis, J. (2009) Molecular mechanisms of mTOR-mediated translational control. Nat. Rev. Mol. Cell. Biol. 10, 307-318 CrossRef PubMed
37. Bar-Peled, L. and Sabatini, D.M. (2014) Regulation of mTORC1 by amino acids. Trends Cell Biol. 24, 400-406 CrossRef PubMed
38. Cantley, L.C. (2002) The phosphoinositide 3-kinase pathway. Science 296, 1655-1657 CrossRef PubMed
39. Yuan, T.L. and Cantley, L.C. (2008) PI3K pathway alterations in cancer: Variations on a theme. Oncogene 27, 5497-5510 CrossRef PubMed
40. Pearce, L.R., Huang, X., Boudeau, J., Pawlowski, R., Wullschleger, S., Deak, M., Ibrahim, A.F., Gourlay, R., Magnuson, M.A. and Alessi, D.R. (2007) Identification of Protor as a novel Rictor-binding component of mTOR complex-2. Biochem. J. 405, 513-522 CrossRef PubMed
41. Kandel, E.S. and Hay, N. (1999) The regulation and activities of the multifunctional serine/threonine kinase Akt/PKB. Exp. Cell Res. 253, 210-229 CrossRef PubMed
42. Brazil, D.P. and Hemmings, B.A. (2001) Ten years of protein kinase B signalling: A hard Akt to follow. Trends Biochem. Sci. 26, 657-664 CrossRef PubMed
43. Scheid, M.P. and Woodgett, J.R. (2001) Phosphatidylinositol 3' kinase signaling in mammary tumorigenesis. J. Mammary Gland Biol. Neoplasia 6, 83-99 CrossRef PubMed
44. Sarbassov, D.D., Ali, S.M., Sengupta, S., Sheen, J.H., Hsu, P.P., Bagley, A.F., Markhard, A.L. and Sabatini, D.M. (2006) Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB. Mol. Cell 22, 159-168 CrossRef PubMed
45. Inoki, K., Li, Y., Zhu, T., Wu, J. and Guan, K.L. (2002) TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signalling. Nat. Cell Biol. 4, 648-657 CrossRef PubMed
46. Manning, J., Beutler, K., Knepper, M.A. and Vehaskari, V.M. (2002) Upregulation of renal BSC1 and TSC in prenatally programmed hypertension. Am. J. Physiol. Renal Physiol. 283, F202-F206 CrossRef PubMed
47. Dibble, C.C., Elis, W., Menon, S., Qin, W., Klekota, J., Asara, J.M., Finan, P.M., Kwiatkowski, D.J., Murphy, L.O. and Manning, B.D. (2012) TBC1D7 is a third subunit of the TSC1-TSC2 complex upstream of mTORC1. Mol. Cell 47, 535-546 CrossRef PubMed
48. Gingras, A.C., Gygi, S.P., Raught, B., Polakiewicz, R.D., Abraham, R.T., Hoekstra, M.F., Aebersold, R. and Sonenberg, N. (1999) Regulation of 4E-BP1 phosphorylation: A novel two-step mechanism. Genes Dev. 13, 1422-1437 CrossRef PubMed
49. Gingras, A.C., Kennedy, S.G., O'Leary, M.A., Sonenberg, N. and Hay, N. (1998) 4E-BP1, a repressor of mRNA translation, is phosphorylated and inactivated by the Akt(PKB) signaling pathway. Genes Dev. 12, 502-513 CrossRef PubMed
50. Mamane, Y., Petroulakis, E., Martineau, Y., Sato, T.A., Larsson, O., Rajasekhar, V.K. and Sonenberg, N. (2007) Epigenetic activation of a subset of mRNAs by eIF4E explains its effects on cell proliferation. PLoS One 2, e242 CrossRef PubMed
51. Larsson, O., Sonenberg, N. and Nadon, R. (2010) Identification of differential translation in genome wide studies. Proc. Natl. Acad. Sci. U.S.A. 107, 21487-21492 CrossRef PubMed
52. Lazaris-Karatzas, A., Montine, K.S. and Sonenberg, N. (1990) Malignant transformation by a eukaryotic initiation factor subunit that binds to mRNA 5' cap. Nature 345, 544-547 CrossRef PubMed
53. Lazaris-Karatzas, A. and Sonenberg, N. (1992) The mRNA 5' cap-binding protein, eIF-4E, cooperates with v-myc or E1A in the transformation of primary rodent fibroblasts. Mol. Cell. Biol. 12, 1234-1238 PubMed
54. Avdulov, S., Li, S., Michalek, V., Burrichter, D., Peterson, M., Perlman, D.M., Manivel, J.C., Sonenberg, N., Yee, D., Bitterman, P.B. and Polunovsky, V.A. (2004) Activation of translation complex eIF4F is essential for the genesis and maintenance of the malignant phenotype in human mammary epithelial cells. Cancer Cell 5, 553-563 CrossRef PubMed
55. Rousseau, D., Kaspar, R., Rosenwald, I., Gehrke, L. and Sonenberg, N. (1996) Translation initiation of ornithine decarboxylase and nucleocytoplasmic transport of cyclin D1 mRNA are increased in cells overexpressing eukaryotic initiation factor 4E. Proc. Natl. Acad. Sci. U.S.A. 93, 1065-1070 CrossRef PubMed
56. Schneider, R.J. and Sonenberg, N. (2007) Translational Control in Cancer Development and Progression. Cold Spring Harbor Monograph Archive, Cold Spring Harbor, NY
57. Rinker-Schaeffer, C.W., Graff, J.R., De Benedetti, A., Zimmer, S.G. and Rhoads, R.E. (1993) Decreasing the level of translation initiation factor 4E with antisense RNA causes reversal of ras-mediated transformation and tumorigenesis of cloned rat embryo fibroblasts. Int. J. Cancer 55, 841-847 CrossRef PubMed
58. Wendel, H.G., De Stanchina, E., Fridman, J.S., Malina, A., Ray, S., Kogan, S., Cordon-Cardo, C., Pelletier, J. and Lowe, S.W. (2004) Survival signalling by Akt and eIF4E in oncogenesis and cancer therapy. Nature 428, 332-337 CrossRef PubMed
59. Ruggero, D., Montanaro, L., Ma, L., Xu, W., Londei, P., Cordon-Cardo, C. and Pandolfi, P.P. (2004) The translation factor eIF-4E promotes tumor formation and cooperates with c-Myc in lymphomagenesis. Nat. Med. 10, 484-486 CrossRef PubMed
60. Waskiewicz, A.J., Johnson, J.C., Penn, B., Mahalingam, M., Kimball, S.R. and Cooper, J.A. (1999) Phosphorylation of the cap-binding protein eukaryotic translation initiation factor 4E by protein kinase Mnk1 in vivo. Mol. Cell. Biol. 19, 1871-1880 PubMed
61. Fukunaga, R. and Hunter, T. (1997) MNK1, a new MAP kinase-activated protein kinase, isolated by a novel expression screening method for identifying protein kinase substrates. EMBO J. 16, 1921-1933 CrossRef PubMed
62. Topisirovic, I., Ruiz-Gutierrez, M. and Borden, K.L. (2004) Phosphorylation of the eukaryotic translation initiation factor eIF4E contributes to its transformation and mRNA transport activities. Cancer Res. 64, 8639-8642 CrossRef PubMed
63. Wendel, H.G., Silva, R.L., Malina, A., Mills, J.R., Zhu, H., Ueda, T., Watanabe-Fukunaga, R., Fukunaga, R., Teruya-Feldstein, J., Pelletier, J. and Lowe, S.W. (2007) Dissecting eIF4E action in tumorigenesis. Genes Dev. 21, 3232-3237 CrossRef PubMed
64. Furic, L., Rong, L., Larsson, O., Koumakpayi, I.H., Yoshida, K., Brueschke, A., Petroulakis, E., Robichaud, N., Pollak, M., Gaboury, L.A. et al. (2010) eIF4E phosphorylation promotes tumorigenesis and is associated with prostate cancer progression. Proc. Natl. Acad. Sci. U.S.A. 107, 14134-14139 CrossRef PubMed
65. Robichaud, N., Del Rincon, S.V., Huor, B., Alain, T., Petruccelli, L.A., Hearnden, J., Goncalves, C., Grotegut, S., Spruck, C.H., Furic, L. et al. (2014) Phosphorylation of eIF4E promotes EMT and metastasis via translational control of SNAIL and MMP-3. Oncogene 34, 2032-2042 CrossRef PubMed
66. Trotman, L.C., Niki, M., Dotan, Z.A., Koutcher, J.A., Cristofano, A., Xiao, A., Khoo, A.S., Roy-Burman, P., Greenberg, N.M., Dyke, T. et al. (2003) Pten dose dictates cancer progression in the prostate. PLoS Biol. 1, CrossRef
67. Konicek, B.W., Stephens, J.R., McNulty, A.M., Robichaud, N., Peery, R.B., Dumstorf, C.A., Dowless, M.S., Iversen, P.W., Parsons, S., Ellis, K.E. et al. (2011) Therapeutic inhibition of MAP kinase interacting kinase blocks eukaryotic initiation factor 4E phosphorylation and suppresses outgrowth of experimental lung metastases. Cancer Res. 71, 1849-1857 CrossRef PubMed
68. Nasr, Z., Robert, F., Jr, J.A., Muller, W.J. and Pelletier, J. (2013) eIF4F suppression in breast cancer affects maintenance and progression. Oncogene 32, 861-871 CrossRef PubMed
69. Friedl, P. and Alexander, S. (2011) Cancer invasion and the microenvironment: Plasticity and reciprocity. Cell 147, 992-1009 CrossRef PubMed
70. Xu, J., Lamouille, S. and Derynck, R. (2009) TGF-beta-induced epithelial to mesenchymal transition. Cell Res. 19, 156-172 CrossRef PubMed
71. Proud, C.G. (2014) Mnks, eIF4E phosphorylation and cancer. Biochim. Biophys. Acta 766-773
72. Armengol, G., Rojo, F., Castellvi, J., Iglesias, C., Cuatrecasas, M., Pons, B., Baselga, J. and Cajal, S. (2007) funnel factor. Cancer Res. 67, 7551-7555 CrossRef PubMed
73. Pelletier, J., Graff, J., Ruggero, D. and Sonenberg, N. (2015) Targeting the eIF4F translation initiation complex: A critical nexus for cancer development. Cancer Res. 75, 250-263 CrossRef PubMed
74. Liu, Q., Kang, S.A., Thoreen, C.C., Hur, W., Wang, J., Chang, J.W., Markhard, A., Zhang, J., Sim, T., Sabatini, D.M. and Gray, N.S. (2012) Development of ATP-competitive mTOR inhibitors. Methods Mol. Biol. 821, 447-460 CrossRef PubMed
75. Feldman, M.E., Apsel, B., Uotila, A., Loewith, R., Knight, Z.A., Ruggero, D. and Shokat, K.M. (2009) Active-site inhibitors of mTOR target rapamycin-resistant outputs of mTORC1 and mTORC2. PLoS Biol. 7, CrossRef
76. Ilic, N., Utermark, T., Widlund, H.R. and Roberts, T.M. (2011) PI3K-targeted therapy can be evaded by gene amplification along the MYC-eukaryotic translation initiation factor 4E (eIF4E) axis. Proc. Natl. Acad. Sci. U.S.A. 108, E699-E708 CrossRef PubMed
77. Cope, C.L., Gilley, R., Balmanno, K., Sale, M.J., Howarth, K.D., Hampson, M., Smith, P.D., Guichard, S.M. and Cook, S.J. (2014) Adaptation to mTOR kinase inhibitors by amplification of eIF4E to maintain cap-dependent translation. J. Cell Sci. 127, 788-800 CrossRef PubMed
78. Alain, T., Sonenberg, N. and Topisirovic, I. (2012) mTOR inhibitor efficacy is determined by the eIF4E/4E-BP ratio. Oncotarget 3, 1491-1492 PubMed
79. Dowling, R.J., Topisirovic, I., Alain, T., Bidinosti, M., Fonseca, B.D., Petroulakis, E., Wang, X., Larsson, O., Selvaraj, A., Liu, Y. et al. (2010) mTORC1-mediated cell proliferation, but not cell growth, controlled by the 4E-BPs. Science 328, 1172-1176 CrossRef PubMed
80. Graff, J.R., Konicek, B.W., Vincent, T.M., Lynch, R.L., Monteith, D., Weir, S.N., Schwier, P., Capen, A., Goode, R.L., Dowless, M.S. et al. (2007) Therapeutic suppression of translation initiation factor eIF4E expression reduces tumor growth without toxicity. J. Clin. Invest. 117, 2638-2648 CrossRef PubMed
81. Yanagiya, A., Suyama, E., Adachi, H., Svitkin, Y.V., Aza-Blanc, P., Imataka, H., Mikami, S., Martineau, Y., Ronai, Z.A. and Sonenberg, N. (2012) Translational homeostasis via the mRNA cap-binding protein, eIF4E. Mol. Cell 46, 847-858 CrossRef PubMed
82. Hou, J., Lam, F., Proud, C. and Wang, S. (2012) Targeting Mnks for cancer therapy. Oncotarget 3, 118-131 PubMed
83. Knauf, U., Tschopp, C. and Gram, H. (2001) Negative regulation of protein translation by mitogen-activated protein kinase-interacting kinases 1 and 2. Mol. Cell Biol. 21, 5500-5511 CrossRef PubMed
84. Konicek, B.W., Dumstorf, C.A. and Graff, J.R. (2008) Targeting the eIF4F translation initiation complex for cancer therapy. Cell Cycle 7, 2466-2471 CrossRef PubMed
85. Diab, S., Teo, T., Kumarasiri, M., Li, P., Yu, M., Lam, F., Basnet, S.K., Sykes, M.J., Albrecht, H., Milne, R. and Wang, S. (2014) Discovery of 5-(2-(phenylamino)pyrimidin-4-yl)thiazol-2(3H)-one derivatives as potent Mnk2 inhibitors: Synthesis, SAR analysis and biological evaluation. ChemMedChem 9, 962-972 CrossRef PubMed
86. Ueda, T., Sasaki, M., Elia, A.J., Chio, II, Hamada, K., Fukunaga, R. and Mak, T.W. (2010) Combined deficiency for MAP kinase-interacting kinase 1 and 2 (Mnk1 and Mnk2) delays tumor development. Proc. Natl. Acad. Sci. U.S.A. 107, 13984-13990 CrossRef PubMed
87. Papadopoulos, E., Jenni, S., Kabha, E., Takrouri, K.J., Yi, T., Salvi, N., Luna, R.E., Gavathiotis, E., Mahalingam, P., Arthanari, H. et al. (2014) Structure of the eukaryotic translation initiation factor eIF4E in complex with 4EGI-1 reveals an allosteric mechanism for dissociating eIF4G. Proc. Natl. Acad. Sci. U.S.A. 111, E3187-E3195 CrossRef PubMed
88. Fan, S., Li, Y., Yue, P., Khuri, F.R. and Sun, S.Y. (2010) The eIF4E/eIF4G interaction inhibitor 4EGI-1 augments TRAIL-mediated apoptosis through c-FLIP down-regulation and DR5 induction independent of inhibition of cap-dependent protein translation. Neoplasia 12, 346-356 CrossRef PubMed
89. Chen, L., Aktas, B.H., Wang, Y., He, X., Sahoo, R., Zhang, N., Denoyelle, S., Kabha, E., Yang, H., Freedman, R.Y. et al. (2012) Tumor suppression by small molecule inhibitors of translation initiation. Oncotarget 3, 869-881 PubMed
90. Descamps, G., Gomez-Bougie, P., Tamburini, J., Green, A., Bouscary, D., Maiga, S., Moreau, P., Gouill, S., Pellat-Deceunynck, C. and Amiot, M. (2012) The cap-translation inhibitor 4EGI-1 induces apoptosis in multiple myeloma through Noxa induction. Br. J. Cancer 106, 1660-1667 CrossRef PubMed
91. Attar-Schneider, O., Drucker, L., Zismanov, V., Tartakover-Matalon, S. and Lishner, M. (2014) Targeting eIF4GI translation initiation factor affords an attractive therapeutic strategy in multiple myeloma. Cell. Signal. 26, 1878-1887 CrossRef PubMed
92. Yi, T., Kabha, E., Papadopoulos, E. and Wagner, G. (2014) 4EGI-1 targets breast cancer stem cells by selective inhibition of translation that persists in CSC maintenance, proliferation and metastasis. Oncotarget 5, 6028-6037 PubMed
93. Mahalingam, P., Takrouri, K., Chen, T., Sahoo, R., Papadopoulos, E., Chen, L., Wagner, G., Aktas, B.H., Halperin, J.A. and Chorev, M. (2014) Synthesis of rigidified eIF4E/eIF4G inhibitor-1 (4EGI-1) mimetic and their in vitro characterization as inhibitors of protein-protein interaction. J. Med. Chem. 57, 5094-5111 CrossRef PubMed
94. Takrouri, K., Chen, T., Papadopoulos, E., Sahoo, R., Kabha, E., Chen, H., Cantel, S., Wagner, G., Halperin, J.A., Aktas, B.H. and Chorev, M. (2014) Structure-activity relationship study of 4EGI-1, small molecule eIF4E/eIF4G protein-protein interaction inhibitors. Eur. J. Med. Chem. 77, 361-377 CrossRef PubMed
95. Yefidoff-Freedman, R., Chen, T., Sahoo, R., Chen, L., Wagner, G., Halperin, J.A., Aktas, B.H. and Chorev, M. (2014) 3-substituted indazoles as configurationally locked 4EGI-1 mimetics and inhibitors of the eIF4E/eIF4G interaction. Chembiochem 15, 595-611 CrossRef PubMed
96. Lukhele, S., Bah, A., Lin, H., Sonenberg, N. and Forman-Kay, J.D. (2013) Interaction of the eukaryotic initiation factor 4E with 4E-BP2 at a dynamic bipartite interface. Structure 21, 2186-2196 CrossRef PubMed
97. Igreja, C., Peter, D., Weiler, C. and Izaurralde, E. (2014) 4E-BPs require non-canonical 4E-binding motifs and a lateral surface of eIF4E to repress translation. Nat. Commun. 5, 4790 CrossRef PubMed
98. Peter, D., Igreja, C., Weber, R., Wohlbold, L., Weiler, C., Ebertsch, L., Weichenrieder, O. and Izaurralde, E. (2015) Molecular architecture of 4E-BP translational inhibitors bound to eIF4E. Mol. Cell 57, 1074-1087 CrossRef PubMed
99. Bah, A., Vernon, R.M., Siddiqui, Z., Krzeminski, M., Muhandiram, R., Zhao, C., Sonenberg, N., Kay, L.E. and Forman-Kay, J.D. (2015) Folding of an intrinsically disordered protein by phosphorylation as a regulatory switch. Nature 519, 106-109 CrossRef PubMed
100. Jia, Y., Polunovsky, V., Bitterman, P.B. and Wagner, C.R. (2012) Cap-dependent translation initiation factor eIF4E: An emerging anticancer drug target. Med. Res. Rev. 32, 786-814 CrossRef PubMed
101. Li, S., Jia, Y., Jacobson, B., McCauley, J., Kratzke, R., Bitterman, P.B. and Wagner, C.R. (2013) Treatment of breast and lung cancer cells with a N-7 benzyl guanosine monophosphate tryptamine phosphoramidate pronucleotide (4Ei-1) results in chemosensitization to gemcitabine and induced eIF4E proteasomal degradation. Mol. Pharm. 10, 523-531 CrossRef PubMed
102. Ghosh, B., Benyumov, A.O., Ghosh, P., Jia, Y., Avdulov, S., Dahlberg, P.S., Peterson, M., Smith, K., Polunovsky, V.A., Bitterman, P.B. and Wagner, C.R. (2009) Nontoxic chemical interdiction of the epithelial-to-mesenchymal transition by targeting cap-dependent translation. ACS Chem. Biol. 4, 367-377 CrossRef PubMed
103. Chen, E.Z., Jacobson, B.A., Patel, M.R., Okon, A.M., Li, S., Xiong, K., Vaidya, A.J., Bitterman, P.B., Wagner, C.R. and Kratzke, R.A. (2014) Small-molecule inhibition of oncogenic eukaryotic protein translation in mesothelioma cells. Invest. New Drugs 32, 598-603 CrossRef PubMed
104. Chen, X., Kopecky, D.J., Mihalic, J., Jeffries, S., Min, X., Heath, J., Deignan, J., Lai, S., Fu, Z., Guimaraes, C. et al. (2012) Structure-guided design, synthesis, and evaluation of guanine-derived inhibitors of the eIF4E mRNA-cap interaction. J. Med. Chem. 55, 3837-3851 CrossRef PubMed
105. Chu, J. and Pelletier, J. (2014) Targeting the eIF4A RNA helicase as an anti-neoplastic approach. Biochim. Biophys. Acta 781-791
106. Marusyk, A., Almendro, V. and Polyak, K. (2012) Intra-tumour heterogeneity: A looking glass for cancer? Rev. Cancer 12, 323-334 CrossRef
107. Polyak, K. (2014) Tumor heterogeneity confounds and illuminates: A case for Darwinian tumor evolution. Nat. Med. 20, 344-346 CrossRef PubMed
108. Onsum, M.D., Geretti, E., Paragas, V., Kudla, A.J., Moulis, S.P., Luus, L., Wickham, T.J., McDonagh, C.F., Macbeath, G. and Hendriks, B.S. (2013) Single-cell quantitative HER2 measurement identifies heterogeneity and distinct subgroups within traditionally defined HER2-positive patients. Am. J. Pathol. 183, 1446-1460 CrossRef PubMed
109. Rao, C., Shetty, J. and Prasad, K.H. (2013) Immunohistochemical profile and morphology in triple - negative breast cancers. J. Clin. Diagn. Res. 7, 1361-1365 PubMed
110. Wolff, A.C., Hammond, M.E., Schwartz, J.N., Hagerty, K.L., Allred, D.C., Cote, R.J., Dowsett, M., Fitzgibbons, P.L., Hanna, W.M., Langer, A. et al. (2007) American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J. Clin. Oncol. 25, 118-145 CrossRef PubMed
111. Widakowich, C., de Castro, G., de Azambuja, E., Dinh, P. and Awada, A. (2007) Review: Side effects of approved molecular targeted therapies in solid cancers. Oncologist 12, 1443-1455 CrossRef PubMed
112. Larkin, J., Ascierto, P.A., Dreno, B., Atkinson, V., Liszkay, G., Maio, M., Mandala, M., Demidov, L., Stroyakovskiy, D., Thomas, L. et al. (2014) Combined vemurafenib and cobimetinib in BRAF-mutated melanoma. N. Engl. J. Med. 371, 1867-1876 CrossRef PubMed
113. Ramon, Y.C.S., De Mattos-Arruda, L., Sonenberg, N., Cortes, J. and Peg, V. (2014) The intra-tumor heterogeneity of cell signaling factors in breast cancer: P4E-BP1 and peIF4E are diffusely expressed and are real potential targets. Clin. Transl. Oncol. 16, 937-941 CrossRef PubMed
114. Boussemart, L., Malka-Mahieu, H., Girault, I., Allard, D., Hemmingsson, O., Tomasic, G., Thomas, M., Basmadjian, C., Ribeiro, N., Thuaud, F. et al. (2014) eIF4F is a nexus of resistance to anti-BRAF and anti-MEK cancer therapies. Nature 513, 105-109 CrossRef PubMed
115. Gkogkas, C.G., Khoutorsky, A., Ran, I., Rampakakis, E., Nevarko, T., Weatherill, D.B., Vasuta, C., Yee, S., Truitt, M., Dallaire, P. et al. (2013) Autism-related deficits via dysregulated eIF4E-dependent translational control. Nature 493, 371-377 CrossRef PubMed
116. Gkogkas, C.G., Khoutorsky, A., Cao, R., Jafarnejad, S.M., Prager-Khoutorsky, M., Giannakas, N., Kaminari, A., Fragkouli, A., Nader, K., Price, T.J. et al. (2014) Pharmacogenetic inhibition of eIF4E-dependent Mmp9 mRNA translation reverses fragile X syndrome-like phenotypes. Cell Rep. 9, 1742-1755 CrossRef PubMed